Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Children's Zyrtec(R) Chewable Tablets for Allergy Relief and Children's Zyrtec(R) Chewable Tablets for Hives Relief
Date:1/14/2008

DETROIT, Jan. 14 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride Chewable Tablets, "over-the-counter", (OTC), 5 mg and 10 mg (Cetirizine HCl Chewable).

Cetirizine HCl Chewable, which will be marketed as two separate OTC products in two strengths, 5 mg and 10 mg, is an antihistamine drug, which is used to treat allergies, hives, and other allergic inflammatory conditions. These new products are bioequivalent to Children's Zyrtec(R) chewable tablets for allergy relief and Children's Zyrtec(R) for hives relief, registered trademarks of Johnson & Johnson.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are extremely pleased to receive this FDA final approval for our second generic "over-the-counter" product to be added to our current portfolio of prescription products. We feel that Cetirizine HCl Chewable complements our previously announced FDA final approval of Cetirizine Hydrochloride Tablets, 5 mg and 10 mg, and both products will be positive additions to our portfolio by expanding our product offerings. Children's Zyrtec(R) chewable tablets for allergy relief have just been approved for the OTC market and we are pleased to be able to market a generic OTC version as an alternative. It previously was marketed strictly as a prescription product under the Zyrtec(R) brand name, a registered trademark of Pfizer Inc. where it had done over $80 million in prescription sales. We plan to market these products to the generic pharmaceutical and OTC markets immediately."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... PA (PRWEB) , ... May 24, 2016 , ... ... manufacturer of safety signs and safety labels , has been ... “Understanding Symbols: Laser Labels.” , The eiXtra e-newsletter provides electroindustry professionals with manufacturer, ...
(Date:5/24/2016)... ... 2016 , ... Since 1946, the doctors and staff at Clifton Dental Associates ... patient arrives at the office, the staff will make them feel welcome and comfortable. ... create a complete dental treatment plan that is unique to each smile. , Dr. ...
(Date:5/24/2016)... ... ... PhysicianOne Urgent Care, advocators in helping their patients lead the healthiest lives possible, updates ... spring. , The official tick season kicks off in May across the states ... themselves to their prey while they feed off their blood. Like other similar biting ...
(Date:5/24/2016)... (PRWEB) , ... May 24, ... ... announcement of Essette Dashboard, its highly anticipated, web-based software module. The cutting-edge ... The application’s “secret sauce”? Integration with Izenda’s self-service business intelligence solution and ...
(Date:5/24/2016)... ... May 24, 2016 , ... NutraPre today announced the ... pregnant women to prevent morning sickness and promote overall heath. Engineered with advanced ... and taste of water. , “Imagine a pregnancy without morning sickness,” NutraPre CEO ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... LONDON , May 23, 2016 ... Surgical Devices, Diagnostics and Monitoring, and Vision Care ... Market? Which areas are going to grow at the ... potential revenues to 2026, assessing data, trends, opportunities and ... tables, charts, and graphs. Discover the most lucrative areas ...
(Date:5/23/2016)... 2016 The global  reprocessed medical ... by 2022, according to a new study by Grand ... coupled with the lack of centralized support for waste ... the demand for reprocessed medical devices market. Additionally, the ... that of the original device is the high impact ...
(Date:5/20/2016)... , May 20, 2016 ... Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors ... Drugs - This New Study Reveals Selling Opportunities ... ,What is the future of ... latest technological and commercial analysis. Staying ahead in ...
Breaking Medicine Technology: